<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03075670</url>
  </required_header>
  <id_info>
    <org_study_id>NN7999-4260</org_study_id>
    <secondary_id>2016-001149-25</secondary_id>
    <secondary_id>U1111-1180-7154</secondary_id>
    <nct_id>NCT03075670</nct_id>
  </id_info>
  <brief_title>A Trial Comparing Nonacog Beta Pegol (N9-GP) and ALPROLIX® in Patients With Haemophilia B</brief_title>
  <acronym>paradigm™7</acronym>
  <official_title>A Trial Comparing the Pharmacokinetics of Nonacog Beta Pegol (N9-GP) and ALPROLIX® in Patients With Haemophilia B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Europe and the United States of America. The aim of this trial is
      to compare the pharmacokinetics (the exposure of the trial drug in the body) of nonacog beta
      pegol (N9-GP) and ALPROLIX® in patients with haemophilia B.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 7, 2017</start_date>
  <completion_date type="Actual">December 8, 2017</completion_date>
  <primary_completion_date type="Actual">December 8, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the factor IX activity-time curve from 0 to infinity dose-normalised to 50 IU/kg</measure>
    <time_frame>From time 0 (dosing) up to 240 hours post-dose</time_frame>
    <description>Calculated based on plasma FIX activity measured in blood</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum activity dose-normalised to 50 IU/kg (Cmax,norm)</measure>
    <time_frame>From time 0 (dosing) up to 240 hours post-dose</time_frame>
    <description>Calculated based on plasma FIX activity measured in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incremental recovery at 30 minutes (IR30min)</measure>
    <time_frame>At 30 minutes</time_frame>
    <description>Calculated based on plasma FIX activity measured in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life (t½)</measure>
    <time_frame>From time 0 (dosing) up to 240 hours post-dose</time_frame>
    <description>Calculated based on plasma FIX activity measured in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL)</measure>
    <time_frame>From time 0 (dosing) up to 240 hours post-dose</time_frame>
    <description>Calculated based on plasma FIX activity measured in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the activity-time curve</measure>
    <time_frame>From time 0 (dosing) up to 240 hours post-dose</time_frame>
    <description>Calculated based on plasma FIX activity measured in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum activity (Cmax)</measure>
    <time_frame>From time 0 (dosing) up to 240 hours post-dose</time_frame>
    <description>Calculated based on plasma FIX activity measured in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activity at 30 minutes (C30min)</measure>
    <time_frame>at 30 minutes</time_frame>
    <description>Calculated based on plasma FIX activity measured in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activity at 168 hours (C168h)</measure>
    <time_frame>At 168 hours</time_frame>
    <description>Calculated based on plasma FIX activity measured in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incremental recovery at maximum activity (IRCmax)</measure>
    <time_frame>From time 0 (dosing) up to 240 hours post-dose</time_frame>
    <description>Calculated based on plasma FIX activity measured in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum activity (tmax)</measure>
    <time_frame>From time 0 (dosing) up to 240 hours post-dose</time_frame>
    <description>Calculated based on plasma FIX activity measured in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution during terminal phase (Vz)</measure>
    <time_frame>From time 0 (dosing) up to 240 hours post-dose</time_frame>
    <description>Calculated based on plasma FIX activity measured in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution at steady-state (Vss)</measure>
    <time_frame>From time 0 (dosing) up to 240 hours post-dose</time_frame>
    <description>Calculated based on plasma FIX activity measured in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean residence time (MRT)</measure>
    <time_frame>From time 0 (dosing) up to 240 hours post-dose</time_frame>
    <description>Calculated based on plasma FIX activity measured in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination rate constant</measure>
    <time_frame>From time 0 (dosing) up to 240 hours post-dose</time_frame>
    <description>Calculated based on plasma FIX activity measured in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the activity-time curve from 0 to infinity</measure>
    <time_frame>From time 0 (dosing) up to 240 hours post-dose</time_frame>
    <description>Calculated based on plasma FIX activity measured in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the activity-time curve from 0 to t last</measure>
    <time_frame>From time 0 (dosing) up to 240 hours post-dose</time_frame>
    <description>Calculated based on plasma FIX activity measured in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>From time 0 (dosing) up to 240 hours post-dose</time_frame>
    <description>Count and % of Adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Congenital Bleeding Disorder</condition>
  <condition>Haemophilia B</condition>
  <arm_group>
    <arm_group_label>N9-GP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ALPROLIX®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N9-GP</intervention_name>
    <description>A single dose of 50 IU/kg for intravenous (i.v.) injection</description>
    <arm_group_label>N9-GP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALPROLIX®</intervention_name>
    <description>A single dose of 50 IU/kg for intravenous (i.v.) injection</description>
    <arm_group_label>ALPROLIX®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male, aged 18-70 years (both inclusive) at the time of signing informed consent

          -  Patients with the diagnosis of congenital haemophilia B with factor IX activity below
             or equal to 2%, based on medical records

          -  History of more than 150 exposures days to any factor IX containing products

        Exclusion Criteria:

          -  Known history of factor IX inhibitors

          -  Inhibitors to factor IX (above or equal to 0.6 BU) at screening measured by the
             Nijmegen modified Bethesda method

          -  Immunocompromised (CD4+ T cells below or equal to 200/μL)

          -  Known congenital or acquired coagulation disorders other than haemophilia B

          -  Body mass index above 35 kg/m^²
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016-7710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>East Lansing</city>
        <state>Michigan</state>
        <zip>48823</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10249</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Duisburg</city>
        <zip>47051</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Hannover</city>
        <zip>30159</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Mörfelden-Walldorf</city>
        <zip>64546</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 3, 2017</study_first_submitted>
  <study_first_submitted_qc>March 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 9, 2017</study_first_posted>
  <last_update_submitted>January 11, 2018</last_update_submitted>
  <last_update_submitted_qc>January 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
    <mesh_term>Hemophilia B</mesh_term>
    <mesh_term>Blood Coagulation Disorders</mesh_term>
    <mesh_term>Hemostatic Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>According to the Novo Nordisk disclosure commitment on novonordisk-trials.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

